McDonald's, 4514 Telegraph Avenue, OAKLAND, CA, 94609, USA

Thousands of customers in the Bay Area were in the dark on Wednesday night, according to Pacific Gas and Electric.
By Thursday morning, that number fell to 936 total Bay Area customers impacted by a power outage.
In the Berkeley and Oakland area, more than 2,200 customers... See More were without power due to weather. The outage was reported around 7:24 p.m. Wednesday.

Outage map: pge.com
Source: kron4.com
Source publication date: 2021 10 21 See Less

Embed Report Copy link

A power outage affecting thousands of PG&E customers in Oakland on Wednesday was caused by rainy and windy weather in the area.
The outage was first reported at 10:49 a.m. and affected 3,935 customers at its peak.
The utility's outage map showed neighborhoods on both sides of... See More Broadway north of West MacArthur Boulevard affected by the outage.

Source: ktvu.com
Source publication date: 2021 10 20 See Less

Embed Report Copy link

The largest outage from the weather as of 2:45 a.m. Monday is in San Mateo, where there are 25 separate outages affecting 6,770 customers.
There are another 3,809 customers in San Leandro without power. According to PG&E's outage map, estimates when power will be restored range from... See More none to as late as 9:30 a.m. Monday.

Other locations in the Bay Area where PG&E is listing outages include Crockett, 1,711 customers; San Pablo, 1,698 customers; Richmond, 1,586 customers; Hayward, 1,185 customers; Oakland, 1,160 customers; and Vallejo, 743 customers.

The utility lists 27 other communities around the Bay Area where there are outages affecting fewer than 1,000 customers each.

San Francisco: 1
Peninsula: 5,046
North Bay: 702
East Bay: 9,494
South Bay: 296
Bay Area Total: 15,539

Outage link: pgealerts.alerts.pge.com
Source: abc7news.com
Source publication date: 2021 10 18 See Less

Embed Report Copy link

Thousand of PGE customers without power after rain moves through San Francisco Bay Area 

pgealerts.alerts.pge.com
Source: abc7news.com
Source publication date: 2021 09 19 See Less

Embed Report Copy link

1. The employer failed to properly identify an AirID case and/or suspected case and follow the provisions set forth in T8 CCR 5199(e)(5)(A) and (B). An employee was exposed to a patient with respiratory symptoms on the 5th floor during the first half of July who was... See More exhibiting non-classic symptoms of COVID-19 but was positive for COVID-19. The patient attested to being vaccinated but could not recall when or the type and was then given a COVID-19 test by personnel only wearing an N95. T8 CCR 5199(e)(5) 2. The employer failed to follow implemented source control procedures for a patient showing respiratory symptoms for COVID-19. An employee was exposed to a patient with respiratory symptoms on the 5th floor during the first half of July who was exhibiting non-classic symptoms of COVID-19 but was positive for COVID-19. The patient attested to being vaccinated but could not recall when or the type and was then given a COVID-19 test by personnel only wearing an N95. T8 CCR 5199(e)(1)(B) 3. The employer failed to place a patient in an AII room or area or transfer them to a facility with an AII room or area in a timely manner. An employee was exposed to a patient with respiratory symptoms on the 5th floor during the last half of June who was positive for tuberculosis. The employee was only wearing a N95 for protection, took care of the patient for 8 hours, and when told that the patient was positive, they were told that there was a low risk of transmission. T8 CCR 5199(e)(5)(B)

Alleged Hazards: 3, Employees Exposed: 1
Source: Osha.gov | Receipt Date: 2021-07-15 See Less

Embed Report Copy link

The employer does not enforce and provide engineering controls at the PCU 6 unit to protect employees who are exposed to ATP. On 7/15/21 during the night shift at PCU 6, two COVID-19 patients who were receiving high flow oxygen due to COVID-19 were not placed in... See More negative pressure rooms, exposing approximately 13 employees to health hazards. T8 CCR 5199(e)(5)(B)

Alleged Hazards: 1, Employees Exposed: 13
Source: Osha.gov | Receipt Date: 2021-07-16 See Less

Embed Report Copy link

1. The employer failed to make COVID-19 testing available at no cost to its employees within the exposed group, during employees' paid time immediately and then again one week later after being made aware of an outbreak of 3 or more COVID-19 cases in a 14-day time... See More period in the exposed workplace. T8 CCR 3205.1(b)(1) 2. The employer failed to exclude all employees who had close contact with COVID-19 cases per the requirements of T8 CCR 3205(c)(10). The employer notified employees who had close contact that they could choose to quarantine or continue to work. T8 CCR 3205(9)(B) 3. The employer failed to inform all employees, independent contractors, or other employees who may have been exposed to COVID-19 while at the worksite during the high-risk exposure period of multiple COVID-19 cases. T8 CCR 3205(c)(3)(B)

Alleged Hazards: 3, Employees Exposed: 1
Source: Osha.gov | Receipt Date: 2021-08-10 See Less

Embed Report Copy link

1. The employer failed to implement cleaning and disinfecting procedures, which require identifying and regularly cleaning frequently touched surfaces. Shared vehicles are not being cleaned between shift changes. T8 CCR 3205(c)(7)(B)(1) 2. The employer failed to ensure the toilet facilities are kept clean. There is urine and... See More dirt in the restrooms every day. T8 CCR 3364(b)

Alleged Hazards: 2, Employees Exposed: 1
Source: Osha.gov | Receipt Date: 2021-07-28 See Less

Embed Report Copy link

1) The employer failed to screen employees for COVID-19 symptoms prior to boarding and sharing transportation on the employee shuttle bus that takes employees to and from their personal vehicles for work. T8 CCR 3205.4(d) 2) The employer failed to clean and disinfect all high-contact surfaces (door... See More handles, seatbelt buckles, armrests, etc.) used by a COVID-19 case on August 10, 2021 on the employee shuttle bus that takes employees to and from their personal vehicles for work. T8 CCR 3205.4(e)(1) 3) The employer failed to provide hand sanitizer in the employee shuttle bus that takes employees to and from their personal vehicles for work, and ensure that all drivers and riders sanitize their hands before entering and exiting the vehicle. T8 CCR 3205.4(g) 4) The employer failed to clean and disinfect the employee breakroom in Terminal 2, near Gate 24, after it was used by a COVID-19 case on August 10, 2021. T8 CCR 3205(c)(7)(B)2. 5) The employer failed to investigate and respond to a COVID-19 case in the workplace by: a. not identifying all of the close contacts b. not providing written notice that people at the worksite may have been exposed to COVID-19 c. not making COVID-19 testing available at no cost, during paid time, to all employees of the employer who had a close contact. d. not excluding from the workplace employees who had a close contact until the return to work requirements of subsection (c)(10) are met. T8 CCR 3205(c)(3)(B) & (c)(9)(B)

Alleged Hazards: 5, Employees Exposed: 1
Source: Osha.gov | Receipt Date: 2021-08-10 See Less

Embed Report Copy link

1. The employer failed to ensure that frequently touched surfaces and objects, such as doorknobs, equipment, tools, handrails, handles, and controls in the waiting room and back office are regularly cleaned to prevent the spread of COVID-19 in the workplace. T8 CCR 3205(c)(7)(B)1.

Alleged Hazards: 1, Employees... See More Exposed: 1
Source: Osha.gov | Receipt Date: 2021-08-06 See Less

Embed Report Copy link

This is the 2nd package that just arrives at teterboro and just stops moving what’s the point of charging for next day air if you can’t get it done .. worse thing about this is that’s it’s anxiety medication i desperately need See Less

Embed Report Copy link

Company name: Lupin Pharmaceuticals, Inc.
Brand name: Lupin
Product recalled: Irbesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5 mg and 300mg/12.5 mg
Reason of the recall: API batches above the specification limit for the impurity, N-nitrosoirbesartan
FDA Recall date: October 14, 2021
Recall details: Baltimore, Maryland, October 14, 2021:... See More Lupin Pharmaceuticals Inc. is voluntarily recalling the below-mentioned batches of Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets to the consumer level. As part of Lupin’s ongoing assessment, analysis revealed that certain tested API batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbesartan.

Although Lupin has received no reports of illness that appear to relate to this issue, the company, out of an abundance of caution, is recalling all batches of Irbesartan Tablets USP 75mg, 150mg and 300mg and Irbesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5mg and 300mg/12.5mg in the US.

Lupin discontinued the marketing of Irbesartan and Irbesartan and HCTZ tabs in Jan 2021. Risk Statement: N-nitrosoirbesartan impurity is a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.

From October 8, 2018 (the earliest date of shipment from the manufacturing site of any of the affected batches), to September 30, 2021, Lupin received 4 reports of illness from Irbesartan and 0 reports from Irbesartan and Hydrochlorothiazide. Irbesartan tablet USP is an angiotensin II receptor blocker indicated for treatment of hypertension, to lower blood pressure, diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan Tablets USP 75mg, 150mg and 300mg is packaged in 30 and 90 count bottles and was distributed nationwide in the US to wholesalers, drug chains, mail order pharmacies and supermarkets. Lupin discontinued the marketing of Irbesartan Tablets on Jan 7, 2021. The recalled lots are included in the link below.

Irbesartan and hydrochlorothiazide tablet USP is a combination of irbesartan, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic, indicated for hypertension in patients not adequately controlled with monotherapy or as an initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. Irbesartan and hydrochlorothiazide tablet USP, 150mg/12.5mg and 300mg/12.5mg is packaged in 30 and 90 count bottles and was distributed nationwide in the US to wholesalers, drug chains, mail order pharmacies and supermarkets. Lupin discontinued the marketing of Irbesartan and HCTZ Tablets on Jan 7, 2021. The recalled lots are included in the link below.

Lupin Pharmaceuticals Inc. is notifying its wholesalers, distributors, drug chains, mail order pharmacies and supermarkets by phone and through recall notification and is arranging for the return of all the recalled product lots.

Patients taking, Irbesartan Tablets USP, 75mg, 150mg and 300mg and Irbesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5mg and 300mg/12.5mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.

Wholesalers, distributors and retailers that have Irbesartan Tablets USP, 75mg, 150mg and 300mg and Irbesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5mg and 300mg/12.5mg that are being recalled should discontinue distribution of the recalled product lots immediately and return it to Inmar Rx Solutions, Inc., 635 Vine St, Winston Salem, NC 27101. Tel: (855) 769-3988 / (855) 769-3989.

Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (855) 769-3988 / (855) 769-3989 Monday – Friday 09:00 am to 05:00 pm EST. For reimbursement, please have the recalled lots returned to Inmar Rx Solutions, Inc.; the lot number can be found on the side of the bottle label.

Check the full recall details on fda.gov

Source: FDA See Less

Embed Report Copy link

Shipment was supposed to arrive Friday.  Now I received the following message : Your shipment has potentially been delayed due to emergency or other conditions at 6:46 pm on October 17, 2021. | Symptoms: Other See Less

Embed Report Copy link

FROMM FAMILY FOODS is issuing a voluntary recall of approximately 5,500 cases of Fromm Shredded can Entrée dog food due to potentially elevated levels of Vitamin D.

Consumers should stop feeding the products listed below to their dogs. Potential adverse reactions could occur in all size dogs. ... See More No reports of illness or injury have been reported from consumers to date, however Fromm management has determined it is prudent to pull these four lots out of distribution.

Affected recalled products were distributed at neighborhood pet stores nationwide.

Products are packaged in 12 oz. cans with Best By Date 08/2024. A full list of affected products is:
- Four-Star SHREDDED BEEF IN GRAVY ENTRÉE food for dogs, 12 cans per case, 11877, 12 oz. per can, UPC: 7270511876, Best By Date 082024
- Four-Star SHREDDED CHICKEN IN GRAVY ENTRÉE food for dogs, 12 cans per case, 11881, 12 oz. per can, UPC: 7270511880, Best By Date 082024
- Four-Star SHREDDED CHICKEN IN GRAVY ENTRÉE food for dogs, 12 cans per case, 11879, 12 oz. per can, UPC: 7270511878, Best By Date 082024
-Four-Star SHREDDED TURKEY IN GRAVY ENTRÉE food for dogs, 12 cans per case, 11883, 12 oz. per can, UPC: 7270511882, Best By Date 082024

Dogs ingesting elevated levels of Vitamin D may exhibit symptoms such as vomiting, loss of appetite, increased thirst, increased urination, excessive drooling, and weight loss. Vitamin D when consumed at very high levels can lead to serious health issues in dogs including renal dysfunction. Consumers who have dogs that have consumed any of the affected products and are exhibiting these symptoms should contact their veterinarian.

Check the full recall details on fda.gov

Company name: Fromm Family Foods
Brand name: Fromm Four-Star Nutritionals
Product recalled: Shredded Entrée canned dog food
Reason of the recall: Elevated levels of Vitamin D
FDA Recall date: October 01, 2021

Source: FDA See Less

Embed Report Copy link

USPS lost yet another package at their Teterboro distribution center, reporting "Processing Exception Delay" with no way to know if it will be resolved or not. See Less

Embed Report Copy link

A few weeks ago. My cat got sick from food delivered by chewy. It sat on the porch in the sun. It is wet food. We noticed the color was off but didn’t think it could make him so sick. I had to take him to the... See More vet twice for vomiting and not eating after 1 can. I emailed chewy and sent pictures. They refunded my money and I will only go to the pet store for food for now on. | Symptoms: Nausea, Vomiting See Less

Embed Report Copy link

Priority mail packages bouncing up and down the east coast unnecessarily for days, 4 days later my package is further away from being delivered than when it started. Please fire the guy running this sh*t show. See Less

Embed Report Copy link

Company name: Cook Medical
Brand name: Cook Medical
Product recalled: Transseptal Needle and Transseptal Needle Catheter
Reason of the recall: Complaints of rust on the products
FDA Recall date: October 19, 2021
Recall details: Bloomington, Ind. — On October 8, 2021, Cook Medical issued a global, voluntary... See More recall of the Transseptal Needle and the Transseptal Needle with Catheter. This recall includes all unexpired lots for both of these products. The needles were recalled due to complaints of rust on the products. Use of affected products could result in increased procedural time and inflammatory reactions, including systemic reactions which may lead to permanent impairment or death.

The U.S. Food and Drug Administration (FDA) has not yet classified the recall. Products affected by this recall are:
- Transseptal Needle, INTENDED USE: Intended for transseptal left heart access in both diagnostic and interventional procedures, RPN: TSNC-18-71.0 GPN: G02364 and RPN: TSNC-19-56.0 GPN: G02365, all lot numbers, RANGE OF MANUFACTURE DATES FOR AFFECTED PRODUCTS: October 02, 2016 through July 22, 2021
- Transseptal Needle with Catheter, INTENDED USE: Intended to facilitate transseptal entry into the left atrium, RPN: TSN-17-75.0-ENDRYS, GPN: G19261, all lot numbers, RANGE OF MANUFACTURE DATES FOR AFFECTED PRODUCTS: October 02, 2016 through July 22, 2021

Transseptal Needles, including Transseptal Needles with Catheters, were found to have rust internally, externally, or both. To date, Cook Medical has received no reports of injury or illness related to this recall. Cook has received four complaints where the presence of rust was identified prior to patient contact. However, please be advised that the presence of rust may go undetected by the user. The FDA and other regulatory agencies around the world have been notified of this action.

Potential adverse events: If an affected product is used, potential negative outcomes include increased procedural time (to obtain a replacement device) and inflammatory reactions ranging from local or self-limited reactions to systemic reactions requiring medical intervention. Systemic reactions could potentially lead to permanent impairment or death.

Check the full recall details on fda.gov

Source: FDA See Less

Embed Report Copy link

Company name: Bryant Ranch Prepack
Brand name: Bryant Ranch Prepack
Product recalled: Methocarbamol 500mg
Reason of the recall: Bottles labeled as Methocarbamol 500mg tablets were found to contain Methocarbamol 750mg tablets.
FDA Recall date: October 19, 2021
Recall details: Burbank, CA, Bryant Ranch Prepack is voluntarily recalling... See More 1 lot of Methocarbamol 500mg, Tablets to the consumer level. The bottles labeled as Methocarbamol 500mg Tablets have been found to contain Methocarbamol 750mg Tablets.

Risk Statement: If a patient takes a 750mg Tablet of Methocarbamol instead of the prescribed 500mg Tablets, it potentially could result in Excessive Central Nervous System depression which may result in nausea, sedation, fainting, falls, seizure, coma, and death. Bryant Ranch Prepack has not received any reports of adverse events related to this recall.

The product is used together with rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions and is packaged in a white round bottle with a red and white label, which reads Methocarbamol 500mg packaged in counts of 30 (NDC:7133517952), 60 (NDC: 7133517954), and 90 (NDC:7133517957) pills. The affected Methocarbamol 500mg lots include the following Lot Number 163935/ Exp. Date 10/22. The product can be identified by red and white label with a yellow border at the top and bottom of the label, top of the label reads “Packaged by Bryant Ranch Prepack”, labels are pictured below. The Methocarbamol 500mg was distributed Nationwide to multiple physician offices.

Bryant Ranch Prepack is notifying its distributors and customers by letter and email and is arranging for return of all recalled products. Consumers that have the bottles labeled as Methocarbamol 500mg Tablets which is being recalled should stop using immediately and return to place of purchase and/or contact their physician. Distributors/Physicians should stop distribution and contact Bryant Ranch Prepack to return the product immediately.

Check the full recall details on fda.gov

Source: FDA See Less

Embed Report Copy link

It’s been over 20 days for next-state packages and still have not arrived. See Less

Embed Report Copy link